share_log

6-K: Financial Report for the Period 1 January 2024 to 31 March 2024

6-K: Financial Report for the Period 1 January 2024 to 31 March 2024

诺和诺德 | 6-K：2024年1月1日至3月31日期间的财务报告
美股sec公告 ·  05/02 07:18
Moomoo AI 已提取核心信息
Novo Nordisk A/S, a global healthcare leader in diabetes care, reported a robust financial performance for the first quarter of 2024. The company's sales surged by 22% in Danish kroner and 24% at constant exchange rates (CER) to DKK 65.3 billion. The operating profit followed suit, increasing by 27% in Danish kroner and 30% at CER to DKK 31.8 billion. North America Operations, particularly the US market, contributed significantly to this growth with a 34% increase in sales. The company's Diabetes and Obesity care segment saw a 25% rise in sales, driven by GLP-1 diabetes sales and Obesity care. However, rare disease sales experienced a slight decline. Notably, Novo Nordisk completed the FLOW kidney outcomes trial and received US approval for Wegovy for cardiovascular risk reduction...Show More
Novo Nordisk A/S, a global healthcare leader in diabetes care, reported a robust financial performance for the first quarter of 2024. The company's sales surged by 22% in Danish kroner and 24% at constant exchange rates (CER) to DKK 65.3 billion. The operating profit followed suit, increasing by 27% in Danish kroner and 30% at CER to DKK 31.8 billion. North America Operations, particularly the US market, contributed significantly to this growth with a 34% increase in sales. The company's Diabetes and Obesity care segment saw a 25% rise in sales, driven by GLP-1 diabetes sales and Obesity care. However, rare disease sales experienced a slight decline. Notably, Novo Nordisk completed the FLOW kidney outcomes trial and received US approval for Wegovy for cardiovascular risk reduction. Additionally, the company announced an agreement to acquire three fill-finish sites from Novo Holdings A/S. Looking ahead, Novo Nordisk has raised its 2024 outlook, expecting sales growth of 19-27% and operating profit growth of 22-30% at CER. The company's financial report was prepared in accordance with IAS 34 'Interim Financial Reporting' and Danish disclosure requirements.
糖尿病护理领域的全球医疗保健领导者诺和诺德A/S报告了2024年第一季度的强劲财务表现。该公司的销售额以丹麦克朗计算增长了22％，按固定汇率（CER）计算增长了24％，达到653亿丹麦克朗。营业利润紧随其后，按丹麦克朗计算增长了27％，按CER计算增长了30％，达到318亿丹麦克朗。北美业务，尤其是美国市场，为这一增长做出了重大贡献，销售额增长了34％。在 GLP-1 糖尿病销售和肥胖护理的推动下，该公司的糖尿病和肥胖护理板块的销售额增长了25％。但是，罕见病的销售额略有下降。值得注意的是，诺和诺德完成了FLOW肾脏预后试验，并获得了美国批准的Wegovy用于降低心血管风险。此外，该公司宣布了...展开全部
糖尿病护理领域的全球医疗保健领导者诺和诺德A/S报告了2024年第一季度的强劲财务表现。该公司的销售额以丹麦克朗计算增长了22％，按固定汇率（CER）计算增长了24％，达到653亿丹麦克朗。营业利润紧随其后，按丹麦克朗计算增长了27％，按CER计算增长了30％，达到318亿丹麦克朗。北美业务，尤其是美国市场，为这一增长做出了重大贡献，销售额增长了34％。在 GLP-1 糖尿病销售和肥胖护理的推动下，该公司的糖尿病和肥胖护理板块的销售额增长了25％。但是，罕见病的销售额略有下降。值得注意的是，诺和诺德完成了FLOW肾脏预后试验，并获得了美国批准的Wegovy用于降低心血管风险。此外，该公司宣布了一项从Novo Holdings A/S手中收购三处填充场地的协议。展望未来，诺和诺德上调了其2024年的展望，预计CER的销售额将增长19-27％，营业利润增长22-30％。该公司的财务报告是根据国际会计准则第34号 “中期财务报告” 和丹麦的披露要求编制的。

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息